Login to Your Account



ONE FOR ALL VS. ALL FOR ONE?

Chimerix enrolls dying 7-year-old in pilot study, skirts ethical quandary

By Jennifer Boggs
Managing Editor

Thursday, March 13, 2014

After enduring a social media firestorm this week vilifying the firm for not providing its antiviral candidate brincidofovir to a dying 7-year-old boy on a compassionate use basis, Chimerix Inc. found a way to get the drug to Josh Hardy without setting a potentially dangerous ethical precedent.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription